PA5-61687

antibody from Invitrogen Antibodies

Targeting: CCDC68 SE57-1

Western blot (Data presented on provider website)

Immunohistochemistry (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-61687

Provider

Invitrogen Antibodies

Product name

CCDC68 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: MTTVTVTTEI PPRDKMEDNS ALYESTSAHI IEETEYVKKI RTTLQKIRTQ MFKDEIRHDS TNHKLDAKHC GNLQQGSDSE MDPS Highest antigen sequence identity to the following orthologs: Mouse - 58%, Rat - 57%.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.2 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Coiled-Coil Domain-Containing 68 Downregulation Promotes Colorectal Cancer Cell Growth by Inhibiting ITCH-Mediated CDK4 Degradation.

Wang C, Li H, Wu L, Jiao X, Jin Z, Zhu Y, Fang Z, Zhang X, Huang H, Zhao L
Frontiers in oncology 2021;11:668743

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 CCDC68 is downregulated in CRC tissues and cells. (A) CCDC68 mRNA levels in CRC according to the Cancer Genome Atlas (TCGA) data. (B) The mRNA expression level of CCDC68 in 150 pairs of CRC tissues and paracancerous tissues (normal). (C) Representative IHC images of CCDC68 protein expression in CRC tissues and adjacent normal tissues. (D) Quantification of CCDC68 expression in 150 pairs of CRC tissues and adjacent normal tissues. (E) CCDC68 mRNA expression levels and disease-free survival of patients from TCGA CRC data. (F) Expression of CCDC68 in human CRC cell lines (HCT116, HT29, RKO, and SW480) and in the normal colorectal epithelial cell line HCoEpiC. Data are presented as the mean +- SD, * P < 0.05.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2 CCDC68 overexpression inhibits CRC cell growth in vitro and in vivo. (A) Stable transfectants of HCT116 (Vector) vs. HCT116 (HA-CCDC68) and RKO (Vector) vs. RKO (HA-CCDC68) were identified by western blotting. (B, C) Cell proliferation was detected by ATP assay. Data were analyzed Student''s t -test. (D, E) Anchorage-independent growth was examined by soft agar assay. Cell colonies were counted, and data were presented as colonies per 10,000 cells and analyzed by Student''s t -test. (F) Tumor growth curve for each group. Data were analyzed by Student''s t -test. (G) Representative images of tumors in each group. (H) Statistical analysis of tumor mass in each group; n = 5, Student''s t -test. Data are presented as the mean +- SD. * P < 0.05.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 4 CCDC68 inhibits malignant CRC cell proliferation by downregulating CDK4. (A, D) Stable transformation efficacy was assessed by western blotting in HCT116 (CCDC68) and RKO (CCDC68) cells overexpressing GFP-CDK4. (B, E) A soft agar colony formation assay was used to detect the effect of CDK4 on the proliferation of CRC cells. (C, F) Diagrams comparing the number of cell clones between the control and experimental groups. (G, H) Effect of CDK4 on the G0/G1 phase in HCT116 (CCDC68) and RKO (CCDC68) cells. Data are presented as the mean +- SD and analyzed by Student''s t -test, * P < 0.05.